Russia and Eastern Europe - Emerging or Emerged for Clinical Trials?

You are invited to a luxurious Private Dining Club at the Boston Harbor Hotel, where an evening of Bostonian sumptuosity and elegance will enthrall you.

The paradigm of traditional drug development is shifting as more and more biopharmaceutical organizations look to emerging markets to reduce their clinical study timelines, and hence overall development costs, through more effective patient enrollment. For many, the enticement for conducting clinical trials in emerging markets is over shadowed by the fear of prolonged study start-up times, unknown regulation and logistics requirements, perception of poor quality and political uncertainty.

During the presentation, David Passov, Senior Vice President of Eastern Europe for PRA, and until the recent acquisition by PRA, a President and CEO ClinStar, will explore how to effectively navigate these challenges in Russia and Eastern Europe (EE) and demonstrate how this region is very effective when included as an integral part of your initial study plans, or if needed, in a rescue situation. Mr. Passov will:

-Discuss characteristics and classification of 'emerging' vs 'emerged' for EE geographies

- Consider why Russia and EE are optimal for conducting clinical trials compared to other emerging countries

- Discuss how to successfully navigate cultural differences and regulatory changes in the region in order to achieve expedited approval timelines and recruitment

- Present case studies outlining the operational and opportunity cost savings of conducting trials in these fast enrolling geographies

Join us for an exquisite evening of extravagance and timeless character.



David Passov, MBA
Senior Vice President, Eastern Europe
ClinStar, A PRA Company

David Passov was born in Estonia when it was part of the Soviet Union. He attended Tartu University Medical School prior to moving to the US in 1993. He received a degree in biology from Boston College and following a short basic science research tenure at Massachusetts General Hospital's neuroscience department entered the biopharmaceutical industry in 1996.
Since that time, Mr. Passov has held positions in clinical operations, project management, market research, business development, commercial operations, and general management at various small and large US-based CROs. He also received an MBA from the Executive MBA Program at Northeastern University (Boston, MA) in 2002. Mr. Passov joined ClinStar in 2005 and until the recent acquisition by PRA International, held a position of President and CEO. Currently, he is responsible for management of the Eastern European region and holds a position of Senior Vice President. He is a native Russian speaker and for the past eight years has spent the majority of his time working in Russia and Easter Europe.

Who should attend:

- CEOs

- CMOs

- CSOs

- Heads of R&D

- Therapeutic Area Heads

- Clinical Trial Managers